As we manage the impact of COVID-19, antimicrobial-resistant infections continue to threaten lives everywhere. Every year, antimicrobial-resistant infections lead to 700,000 deaths worldwide.

Webinar learning objectives:

1. Recognize the impact of COVID-19 on AMR 

2. Explain why molecular diagnostic testing plays an important role in providing actionable results for Carbapenemase Producing Organisms

3. Discuss the importance of addressing antimicrobial resistance and the impact of resistance on patients

Join our expert panel with featured guest speaker, Dr. David Nicolau, as they discuss the urgency of the underlying threat behind resistance to last-line antibiotics and the overall impact on the fight against AMR.

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours for those attending from the United States only

Methicillin-resistant Staphylococcus aureus (MRSA) can cause severe problems in the hospital settings, such as bloodstream infections, sepsis, surgical site infections, and death. However, numerous studies have shown that MRSA infections can be prevented. ¹ Preliminary data from a 2022 CDC report on COVID-19 and AMR showed that the hospital-onset MRSA increased by 13% in 2020, ² proving that there is an urgent need to strengthen infection prevention and control practices to combat hospital-onset MRSA.

Rapid and accurate detection of MRSA colonization helps to facilitate targeted infection control practices that can aid workflow to reduce the MRSA transmission and improve overall patient safety.

Webinar objectives:

1. CDC. Methicillin-resistant Staphylococcus aureus (MRSA). General Information. Accessed September 2022. https://www.cdc.gov/mrsa/community/index.html

2. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022,  Accessed September 2022. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours 

Sepsis is a leading cause of hospital deaths, and a decade-long study of hospitalizations across the United States showed that sepsis accounted for more than 50% of hospital deaths.1 If methicillin-resistant staphylococcus aureus (MRSA) is left untreated, it can become severe and cause sepsis.2 Unfortunately, culture-based lab testing methods for gram-positive blood culture bottles require an additional 18-48 hours to determine MRSA.

Without timely results, clinicians often employ empiric treatments, using costly and inadequate antimicrobials that contribute to increased drug resistance. This webinar provides insight into the use of diagnostics to support therapeutic decisions and antimicrobial stewardship.

Webinar objectives:

1. Paoli et al. Crit Care Med. 2018;46(12):1889-1897

2. CDC. Methicillin-resistant Staphylococcus aureus (MRSA). General Information. Accessed August 2022. https://www.cdc.gov/mrsa/community/index.html

Carbapenemase resistance is a growing threat. While antibiotic development is critical, antibiotics are not the solution. In addition to increased mortality rates, CREs are costly to hospitals because they increase the length of stay and treatment costs.

In this symposium, the speakers will discuss the growing concerns for CREs and the role of screening and management to combat them. They will cover the importance of antimicrobial stewardship and how molecular diagnostics can enhance therapeutic strategies and infection control. 

Learning objectives:

• Understand the impact of widespread use of antibiotics during COVID-19
• Discuss the role of screening in the management of multidrug- resistant organisms (MRDOs)
• Recognize the differences among screening methods for MRDOs
• Understand how dealing with carbapenems is an essential component of stewardship
• Learn about CRE mechanisms and the associated impact on therapy
• Describe how the early use of molecular diagnostics provides the opportunity to define optimal therapeutic strategies and enhance infection-control resources

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours 

Webinar Objectives:

• MDRO Threat: Multidrug-resistant organisms (MDROs) like CRE and MRSA pose a serious threat to patients as they cause infections that are difficult to treat with antibiotics.

• Impact on Public Health: The spread of MDROs is a growing public health problem as it contributes to antimicrobial resistance.

• Combating MDROs: Effective prevention methods like molecular PCR testing and active surveillance can help reduce MDRO transmission.

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program 

The world is running out of antibiotics.1 With bacterial antimicrobial resistance (AMR) directly contributing to the deaths of 1.27 million people globally in 2019, taking decisive action now has never been more important.2

This World AMR Awareness Week (WAAW), join our global panel as they share cross-regional expertise, including real-world lived experience of managing outbreaks, meta-analysis and novel diagnostic approaches, in the fight against resistance and threat to last-line antibiotics.

Please note, webinars will be delivered in English

IVD In Vitro Diagnostic Medical Device. May not be available in all countries.

1. World Health Organisation (WHO). July 2022 Report: Antimicrobial Resistance. Accessed April 2023 https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance?_ga=2.20730424.149613883.1682706550-1577130351.1682706550 

2. Murray C, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb;399(10325):629-655.

Host/Moderator

Dr. Beryl Oppenheim
Senior Director, Medical Affairs, Cepheid

The Challenging C's of AMR: CPE, CDI, Candida

Dr. Stephen Brecher
Director of Microbiology, VA Boston Healthcare System, US;
Associate Professor of Pathology and Laboratory Medicine
BU School of Medicine

A Pragmatic Strategy to Tackling Antimicrobial Resistance in Hospitals

Professor David Jenkins
Consultant Medical Microbiologist and Lead Infection Prevention 
Doctor, University Hospitals of Leicester NHS Trust, UK;
President, BSAC (British Society for Antimicrobial Chemotherapy

The Problems and Potential Solutions of Antimicrobial Resistance: A Perspective from a Cancer Hospital in Eastern India

Dr. Sanjay Bhattacharya
Consultant in Microbiology, Tata Medical Center, India

Title: Reigniting the AMR Focus Post-COVID-19: Empowering Action with Diagnostics (US)

Date: Tuesday, October 31, 2023

Time: 10:00am PDT/ 1:00pm EDT

Duration: 1 hour

Antimicrobial resistance (AMR), including superbugs such as CPE, MRSA and VRE, remains some of the greatest challenges to healthcare systems and patient outcomes alike. In the wake of COVID-19, enabling appropriate surveillance, stewardship and infection control have never been more important. 

Join our expert global panel as we examine real-world lived experience, meta-analysis and novel approaches to managing the growing burden of AMR and threat to last-line antibiotics.

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours for those attending from the United States only

Bacterial antimicrobial resistance (AMR) directly contributed to the deaths of 1.27 million people globally in 2019.¹ Superbugs such as MRSA, VRE, and in particular, CPE, now pose some of the greatest challenges to healthcare systems and patient outcomes.

Join our expert panel as we discuss the threat behind resistance to last-line antibiotics, real-world lived experience of managing CPE outbreaks, and the role of precision medicine in the fight against resistance. 

Please note, webinars will be delivered in English

IVD In Vitro Diagnostic Medical Device. May not be available in all countries.

1. Murray C, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb;399(10325):629-655.

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours for those attending from the United States only

Have you ever wondered why PCR testing is still the gold standard for testing respiratory viruses? Join us to learn more on this topic!

During the COVID-19 pandemic, both PCR and rapid antigen testing emerged as key elements in slowing the spread of the virus. However, PCR has been recognized as the gold standard for testing respiratory viruses.

In this webinar, Prof. Gilbert Greub, MD-PhD, FAMH from the University Hospital of Lausanne will present the results of rapid PCR test performance compared to antigen test performance and will discuss the impact of fast PCR testing on the hospital workflow and patient management.

Please note that this webinar will be held in English

Sapete perché i test PCR rimangono il gold standard per il rilevamento dei virus del tratto respiratorio? Partecipate al nostro webinar per scopire di più su questo argomento.

Durante la pandemia di COVID-19, i test PCR ed i test antigenici rapidi hanno giocato un ruolo chiave nel rallentamento della diffusione del virus.

Tuttavia, la PCR è stata riconosciuta come il gold standard per il rilevamento dei virus del tratto respiratorio.In questo webinar, il Prof. Gilbert Greub, MD-PhD, FAMH dell'Ospedale Universitario di Losanna presenterà dati relativi alla performance dei test rapidi PCR rispetto ai test antigenici, discuterà dell'impatto dei test PCR sul flusso di lavoro degli ospedali e sulla gestione dei pazienti.

Si prega di notare che questo webinar si terrà in lingua inglese.

In this interactive webinar, hear from local experts in their field presenting current data on the emergence of circulating influenza A H3N2 viruses with genetic drift in the matrix gene and exploring a clinical experience in the emergency room of rapid multiplex respiratory testing outside the lab and close to the patients.

Join the conversation with Prof Dominique Goedhals and Dr Christophe Martinaud as they highlight the powerful impact of rapid PCR results on improving health outcomes. Our speakers will also explore real-world data and share insights on the importance of integrating fast PCR results into diagnostic pathways for better patient management and overall healthcare.

We are excited to invite you to our upcoming webinar hosted by Cepheid. This presentation will focus on the critical importance of fast turnaround times in respiratory diagnostics.

Join us to learn how rapid, on-demand molecular testing can significantly enhance patient outcomes and streamline healthcare workflows, in contrast to batch testing or rapid antigen detection.

Key discussion points will include the benefits of timely and accurate diagnosis for prompt and appropriate downstream testing, treatment, infection prevention and control activities, and overall healthcare efficiency.

We will also address the limitations of batch testing and rapid antigen detection, such as longer wait times and lower sensitivity, and highlight the advantages of Cepheid's advanced diagnostic technology in delivering quick and reliable results.

This webinar promises to provide valuable insights for healthcare professionals seeking to optimize diagnostic practices and improve patient care.

Join the conversation with Dr. Frenil Munim and Mike Loeffelholz, as they explore how fast and accurate PCR contributes to the agility brought to diagnostics and precision medicine, tailoring treatments to individual patients for enhanced efficacy.

This webinar will cover the following topics:

Rapid and reliable molecular testing for syndromic approach in the era of Antimicrobial and Diagnostic stewardship
Speaker: Dr. Frenil Chetanbhai Munim, MD, DNB (Clinical Microbiology), MBA (Healthcare services), Venus Hospital, India

Emerging and Evolving Respiratory Viruses: Test Design Matters!
Speaker: Mike Loeffelholz, Ph.D., D (ABMM), Vice President Scientific Affairs, Cepheid

Q&A session
Moderated by Dr. Christophe Martinaud (MD, PhD), Director Medical Affairs, EMEA, Cepheid

Join our webinar to hear Dr. Shapiro discuss using Cepheid’s Xpert^® Xpress Strep A PCR testing for diagnosis in his practice. Learn about the potential complications and risks surrounding misdiagnosis and delayed treatment. Hear firsthand how on-demand PCR testing for Strep A was implemented within his patient workflows for better patient care.

Vaginitis is a leading cause of clinic visits by women, with more than 10 million per year in the United States.¹ Limitations with traditional test methods contribute to poor diagnosis, inappropriate treatment, and persistent symptoms.² High-performing PCR tests are available for large batch analyzers but have limited practical use for clinicians due to a lag in reportable results, making appropriate same-day treatment a challenge.³

Webinar objectives: 

• Review the causes of vaginitis/vaginosis, symptoms, and disease burden
• Identify the organisms that cause bacterial vaginosis
• Discuss current diagnostic approaches for vulvovaginitis and their limitations
• Discuss the laboratory impact associated with the implementation of a new NAAT for vaginitis testing

References:

1 Brown H, et al. Improving the Diagnosis of Vulvovaginitis: Perspectives to Align Practice, Guidelines, and Awareness. Population Health Management 2020 23:S1, S-3-S-12
2 Hillier SL, et al. Diagnosis and treatment of vaginal discharge syndromes in community practice settings. Clin Infect Dis. 2021 May 04; 72(9) 1538-1543
3 Gaydos CA, et al. Use of a Rapid Diagnostic for Chlamydia trachomatis and Neisseria gonorrhoeae for Women in the Emergency Department Can Improve Clinical Management: Report of a Randomized Clinical Trial. Ann Emerg Med. 2019 Jul; 74(1) 36-44

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours 

Join us during Medical Laboratory Professionals Week to learn about rapid on-demand molecular tests for sexual and women's health.

Webinar objectives:

• Discuss the most recent CDC surveillance data for STDs
• Explain the benefits of rapid on-demand molecular diagnostics compared to traditional methods and batch testing
• Identify common molecular testing options for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhoeae, and Vaginitis
• Understand key considerations for implementing a new molecular diagnostic

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours 

In the U S., Group B Streptococcus (GBS) remains a leading cause of early-onset neonatal sepsis Rates of maternal colonization have not changed, but universal antenatal screening and intrapartum antibiotic prophylaxis {IAP) have decreased early-onset disease.¹

Webinar Objectives:

•    Learn about the clinical importance of GBS testing in the
prevention of neonatal sepsis

•    Review the most recent AGOG guidelines, including the timing of screening, test ordering/processing, molecular testing, and clinical treatment

•    Recognize laboratory workflow and test sensitivity differences between culture and NAAT methods

1. Puopolo KM, et al., Committee on Fetus and Newborn, Committee on Infe ctious Disease. Management of infants at risk for group B streptococcal disease. Pediatrics. 2019;144(2).

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours 

Group B Streptococcus (GBS) remains the most common cause of neonatal sepsis and meningitis, prompting the need for earlier and more precise detection. In this interactive webinar, hear from local experts in their field explore the clinical utility and impact on patient management of rapid intrapartum PCR point-of-care testing for GBS

Welcome and Introduction

Clinical use of rapid point-of-care GBS testing in a busy Department of Obstetrics and Microbiology Department

By Dr Rikke Bek Helmig and Dr Jan Berg Gertsen Aarhus University Hospital

Experience sharing and discussion in plenum

Moderated by Dr Rikke Bek Helmig

Closing by Cepheid

Go Beyond the Swab with Dr. Christina Muzny and hear how unleashing the power of PCR testing for vaginitis and STI management can improve comprehensive care for women. Learn about how co-testing STIs and vaginitis with PCR can improve clinical outcomes. 

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program 

Group B streptococcus (GBS) colonization during pregnancy can lead to invasive GBS disease in infants, including meningitis or sepsis, with a high mortality risk. Other outcomes include stillbirths, maternal infections, and prematurity. Listen to the experts.

Please join Dr. Rebecca Lillis for an informative presentation where she will review the current state of vaginitis/vaginosis, limitations of traditional diagnostic methods, and use cases for point-of-care NAAT tests when diagnosing vaginitis/vaginosis.

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program

Join us as we discuss novel molecular diagnostics for STI and vaginal infection co-testing, highlighting the impact of misdiagnosis on treatment outcomes. Discover future areas of research in STI/vaginitis co-testing to improve comprehensive care for women.

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program

Delivery of accurate and early diagnostic tests aids the global effort to end TB. Limited capacity in TB diagnostics impedes the cascade of care, leaving many people undiagnosed. To win the fight against TB, there is a need to strengthen near-patient services with innovative, on-demand, scalable molecular technologies that can provide greater access to rapid diagnosis of multi-drug resistant TB and promote test and treat models

In this virtual session, Professor Jeremiah Chakaya will highlight the challenges in the detection and treatment of multidrug-resistant tuberculosis patients in low-resource settings. Dr. Devasena Gnanashanmugam will present the recent innovations and recommendations in TB diagnosis and treatment. Doctor  Lindiwe Mvusi will cap the session by providing a country-specific Xpert® MTB/XDR implementation road map in South Africa.  

The COVID-19 pandemic has set back efforts in the fight against TB, resulting in a greater need to accelerate the diagnosis of TB¹. Effective TB diagnosis and prompt initiation of an effective treatment regimen rely on rapid and accurate drug-susceptibility testing (DST) for all TB patients².

Xpert MTB/XDR* is a first in class WHO recommended low complexity automated nucleic acid amplification test for the detection of resistance to Isoniazid, fluroquinolones and second-line injectable drugs used for TB treatment².

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in the United States.

* Turnaround times vary by test. See individual Product Inserts for specific turnaround times.

References:

1.Impact of the COVID-19 pandemic on TB detection and mortality in 2020, WHO Technical Document, 22 March 2021. Accessed 16/03/22. https://cdn.who.int/media/docs/default-source/hq-tuberculosis/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020.pdf?sfvrsn=3fdd251c_16&download=true
2. WHO Operational Handbook on Tuberculosis. Module 3: Diagnosis rapid diagnostics for tuberculosis detection, 2021 update. https://www.who.int/publications/i/item/9789240030589 Accessed 09/02/2021.

Tuberculosis is the leading infectious disease killer in the world, claiming 1.5 million lives each year.¹ In 2020, the world saw the first year-over-year mortality increase since 2005. Due to COVID-19, there has been a global reduction in healthcare access and it is feared that this reduction will result in a significant wave of future TB cases.²

Early diagnosis and treatment are essential to the battle against tuberculosis. In this webinar, Dr. Barbaro will describe the current TB challenges in the United States. He will review tuberculosis epidemiology, testing methodologies, and testing guidelines.

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E  1.0 contact hours

US-IVD. In Vitro Diagnostic Medical Device.

References:

1. CDC . Tuberculosis (TB). Accessed Feb 2022 https://www.cdc.gov/globalhealth/newsroom/topics/tb/index.html

2. Pai M, Kasaeva T, Swaminathan S. Covid-19’s Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. January 2022.

In 2018, there were an estimated 61,698 people with chronic myeloid leukemia (CML) in the United States, according to the National Institutes of Health. Even though advances in treatment and care have transformed CML into a manageable disease, several significant challenges remain in monitoring therapeutic response and disease progression.  

Please join us on October 19th to discuss CML and the importance of accurate and fast monitoring with two speakers, Dr. Bijal Parikh and Dr. Yitz Goldstein. Dr. Parikh is the Medical Director of the Barnes-Jewish Hospital Molecular Diagnostics Laboratory and Associate Medical Director of the Molecular Infectious Disease and HLA Laboratories. Dr. Goldstein is the Director of the Genomic Laboratories at Montefiore Medical Center and the Director of Clinical Virology. 

The discussion will touch on the revolution of Tyrosine kinase inhibitors and their resistance, the current CML guidelines, and the clinical impact of different assays. Additionally, our speakers will provide a first-hand perspective on the clinical value of rapid molecular CML monitoring and its effect on patient care. 

Cepheid is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

P.A.C.E. credit hours: 1

External HIV VIral Load XC Launch following WHO prequalification.

In the interactive webinar, hear from experts in their field presenting the clinical background and rationale for a PCR based solution for monitoring Chronic myelogenous leukaemia (CML), Acute lymphocytic leukaemia (ALL)  and acute myelogenous leukaemia (AML) patients. During the webinar, you will also hear about a real-world experience from an experienced user and the latest Cepheid leukaemia product portfolio test.

Agenda:

Introduction of the leukaemia product range by Michael Bates, VP, Medical and Scientific Affairs and Strategy, Oncology, Cepheid

A real-world experience from an experienced user in Europe by Eduardo Anguita, MD, PhD, Haematology Professor, UCM, Hospital Clinico San Carlos Madrid, Spain

Introduction of the new Xpert® NPM1 Mutation test by Willy Natera, Field Application Specialist, Cepheid

Q&A session

Delivery of accurate and early diagnostic tests aids the global effort to end TB. Limited capacity in TB diagnostics impedes the cascade of care, leaving many people undiagnosed. To win the fight against TB, there is a need to strengthen near-patient services with innovative, on-demand, scalable molecular technologies that can provide greater access to rapid diagnosis of multi-drug resistant TB and promote test and treat models

In this virtual session, Professor Jeremiah Chakaya will highlight the challenges in the detection and treatment of multidrug-resistant tuberculosis patients in low-resource settings. Dr. Devasena Gnanashanmugam will present the recent innovations and recommendations in TB diagnosis and treatment. Doctor  Lindiwe Mvusi will cap the session by providing a country-specific Xpert® MTB/XDR implementation road map in South Africa.  

The COVID-19 pandemic has set back efforts in the fight against TB, resulting in a greater need to accelerate the diagnosis of TB¹. Effective TB diagnosis and prompt initiation of an effective treatment regimen rely on rapid and accurate drug-susceptibility testing (DST) for all TB patients².

Xpert MTB/XDR* is a first in class WHO recommended low complexity automated nucleic acid amplification test for the detection of resistance to Isoniazid, fluroquinolones and second-line injectable drugs used for TB treatment².

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in the United States.

* Turnaround times vary by test. See individual Product Inserts for specific turnaround times.

References:

1.Impact of the COVID-19 pandemic on TB detection and mortality in 2020, WHO Technical Document, 22 March 2021. Accessed 16/03/22. https://cdn.who.int/media/docs/default-source/hq-tuberculosis/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020.pdf?sfvrsn=3fdd251c_16&download=true
2. WHO Operational Handbook on Tuberculosis. Module 3: Diagnosis rapid diagnostics for tuberculosis detection, 2021 update. https://www.who.int/publications/i/item/9789240030589 Accessed 09/02/2021.

Lab Week Webinar Part 1 Summary:

PCR (Polymerase Chain Reaction) was invented in 1985. Since that time, major technological advancements have allowed PCR testing to become widely used to support clinical diagnosis and treatment. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover a high-level overview about the basics of PCR. 

Lab Week Webinar Part 2 Summary:

Not all tests are created equal. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover the topics of sensitivity and specificity. She will explain the key considerations when selecting a test and the differences between immunoassay, loop-mediated isothermal amplification (LAMP), and PCR. 

Lab Week Webinar Part 3 Summary:

Today, more than ever, there is a demand for the clinical laboratory to provide fast, accurate, and actionable results for clinicians. 

In this webinar, Dr. Denise Uettwiller-Geiger will review how PCR testing can provide clinicians with fast and accurate results, positively impacting operational efficiencies and improving patient outcomes. 

Lab Week Webinar Part 1 Summary:

PCR (Polymerase Chain Reaction) was invented in 1985. Since that time, major technological advancements have allowed PCR testing to become widely used to support clinical diagnosis and treatment. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover a high-level overview about the basics of PCR. 

Lab Week Webinar Part 2 Summary:

Not all tests are created equal. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover the topics of sensitivity and specificity. She will explain the key considerations when selecting a test and the differences between immunoassay, loop-mediated isothermal amplification (LAMP), and PCR. 

Lab Week Webinar Part 3 Summary:

Today, more than ever, there is a demand for the clinical laboratory to provide fast, accurate, and actionable results for clinicians. 

In this webinar, Dr. Denise Uettwiller-Geiger will review how PCR testing can provide clinicians with fast and accurate results, positively impacting operational efficiencies and improving patient outcomes. 

Lab Week Webinar Part 1 Summary:

PCR (Polymerase Chain Reaction) was invented in 1985. Since that time, major technological advancements have allowed PCR testing to become widely used to support clinical diagnosis and treatment. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover a high-level overview about the basics of PCR. 

Lab Week Webinar Part 2 Summary:

Not all tests are created equal. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover the topics of sensitivity and specificity. She will explain the key considerations when selecting a test and the differences between immunoassay, loop-mediated isothermal amplification (LAMP), and PCR. 

Lab Week Webinar Part 3 Summary:

Today, more than ever, there is a demand for the clinical laboratory to provide fast, accurate, and actionable results for clinicians. 

In this webinar, Dr. Denise Uettwiller-Geiger will review how PCR testing can provide clinicians with fast and accurate results, positively impacting operational efficiencies and improving patient outcomes. 

Over the past 20 years there has been a continuous shift toward decentralization of clinical laboratory testing to in-office testing for a more patient centric approach. With PCR technology advances in speed, ease of use and accuracy in all clinical settings, it is now possible to bring molecular testing closer to the patient to create efficiencies and improve clinical decision making in your practice, thereby achieving enhance patient outcomes, care, and satisfaction.

This presentation will explore changing healthcare trends, review point of care technologies, and discuss the benefits and advantages of leveraging in-office PCR testing.  Currently available testing platforms/methods and performance criteria will be reviewed, with an emphasis on the importance of office-based PCR testing in the era of performance driven healthcare.

Webinar Objectives: 

• Discuss major trends impacting healthcare and its impact to the delivery of services
• Review lateral flow immunoassay and molecular technologies
• Define definitions for diagnostic test performanceDescribe how leveraging in-office PCR testing can improve quality and achieve improved clinical effectiveness for enhanced patient care and satisfaction
• Review the advantages and limitations of current PCR testing options

Join us as we dive into Cepheid C360. A secure, hosted platform that collects and aggregates real-time disease and system surveillance information from any GeneXpert® System. Connecting your GeneXpert® System testing environment to C360, allows for seamless sharing of diagnostic information, while simultaneously optimizing system uptime across your health care system.

Lab Week Webinar Part 1 Summary:

PCR (Polymerase Chain Reaction) was invented in 1985. Since that time, major technological advancements have allowed PCR testing to become widely used to support clinical diagnosis and treatment. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover a high-level overview about the basics of PCR. 

Lab Week Webinar Part 2 Summary:

Not all tests are created equal. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover the topics of sensitivity and specificity. She will explain the key considerations when selecting a test and the differences between immunoassay, loop-mediated isothermal amplification (LAMP), and PCR. 

Lab Week Webinar Part 3 Summary:

Today, more than ever, there is a demand for the clinical laboratory to provide fast, accurate, and actionable results for clinicians. 

In this webinar, Dr. Denise Uettwiller-Geiger will review how PCR testing can provide clinicians with fast and accurate results, positively impacting operational efficiencies and improving patient outcomes. 

Lab Week Webinar Part 1 Summary:

PCR (Polymerase Chain Reaction) was invented in 1985. Since that time, major technological advancements have allowed PCR testing to become widely used to support clinical diagnosis and treatment. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover a high-level overview about the basics of PCR. 

Lab Week Webinar Part 2 Summary:

Not all tests are created equal. 

In this webinar, Dr. Denise Uettwiller-Geiger will cover the topics of sensitivity and specificity. She will explain the key considerations when selecting a test and the differences between immunoassay, loop-mediated isothermal amplification (LAMP), and PCR. 

Lab Week Webinar Part 3 Summary:

Today, more than ever, there is a demand for the clinical laboratory to provide fast, accurate, and actionable results for clinicians. 

In this webinar, Dr. Denise Uettwiller-Geiger will review how PCR testing can provide clinicians with fast and accurate results, positively impacting operational efficiencies and improving patient outcomes.